By contrast, RCC-41-PDX-2/CD133+ subset exhibited a consistent reduced tumor forming efficiency as compared to RCC41-PDX-2 and RCC-41-PDX-2/CD133−. This evidence concerns the gene PROM1 and neoplasm.